Rome

• Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory … Recruiting
  2023-508355-39-00 7 2024-04-20 Relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 4 2024-04-17 Untreated Chronic Lymphocytic Leukemia
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Recruiting
  2024-516563-86-00 4 2024-04-11 Spinal and Bulbar Muscular Atrophy
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroi … Recruiting
  2023-504756-96-00 5 2024-03-22 Recurrent pericarditis, idiopathic or secondary to invasive cardiac pr
• A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antid … Recruiting
  2024-513019-29-00 5 2024-03-22 Major Depression Disorder
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c … Recruiting
  2023-506714-43-00 4 2024-03-15 ALK positive Non-Small Cell Lung Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-504735-41-00 5 2024-03-05 Moderately to Severely Active Crohn's Disease
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie … Recruiting
  2023-506662-31-00 4 2024-02-28 Gastric or gastroesophageal cancer
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul … Recruiting
  2023-504863-17-00 5 2024-02-21 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambul … Recruiting
  2023-503521-19-00 5 2024-02-09 Duchenne muscular dystrophy (DMD)
• Effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty: a single-centre open-label, randomized, cont … Recruiting
  2024-517679-18-00 6 2024-02-09 obesity

Showing 889–912 of 2,096 trials